GlassScriptPhysician profile
Ruth Fisher
NPI 1104584366
$1,796.98
in general payments reported to CMS, 2019-2025
28 companies · $681 in 2025
The $681 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $96.40 · 2023: $361 · 2024: $659 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.62 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Vanda Pharmaceuticals INC. | $111.19 | 2025 | Fanapt |
| Indivior INC. | $102.91 | 2023-2025 | Sublocade |
| Axsome Therapeutics, INC. | $99.77 | 2025 | Symbravo |
| Lilly USA, LLC | $96.64 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $78.76 | 2022-2023 | |
| Mylan Specialty L.P. | $73.00 | 2024 | Yupelri |
| Amgen INC. | $61.74 | 2023-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.66 | 2022-2025 | Caplyta |
| Lundbeck LLC | $52.78 | 2024-2025 | Rexulti, Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.12 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $48.60 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $41.86 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $38.49 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $37.34 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $33.42 | 2023-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $32.85 | 2022-2025 | Trintellix |
| Pfizer INC. | $31.26 | 2024 | |
| Janssen Pharmaceuticals, INC | $25.67 | 2025 | Spravato |
| Verona Pharma, INC. | $25.46 | 2025 | Ohtuvayre |
| Ibsa Pharma INC. | $22.15 | 2025 | Flector, Licart, Tirosint |
| Supernus Pharmaceuticals, INC. | $18.50 | 2025 | Qelbree |
| Viatris Specialty LLC | $18.07 | 2025 | Yupelri |
| Gilead Sciences, INC. | $17.27 | 2025 | |
| Exact Sciences Corporation | $16.40 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $15.91 | 2024 | Voquezna |
| Si-Bone, INC. | $15.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.